Amarin to Host Conference Call on April 13, 2020 to Provide Preliminary First Quarter 2020 Results and Operational Update
April 08 2020 - 4:05PM
Amarin Corporation plc (NASDAQ:AMRN) today announced that it will
host a conference call with management on Monday, April 13, 2020,
at 4:30 p.m. ET to discuss the company's preliminary first quarter
2020 financial results and provide an operational update on matters
including COVID-19, the company’s planned appeal in the ongoing
patent litigation related to VASCEPA® (icosapent ethyl) in the
United States and plans for international expansion.
A live question and answer period is not planned
for the April 13th call as analysts and investors have already
submitted questions to the company covering a wide range of topics,
responses to which management plans to cover during the call. This
conference call is not intended to replace the regularly scheduled
call Amarin plans to hold in connection with its reporting of first
quarter 2020 results. During that quarterly call management plans
to respond to additional questions from analysts and investors.
Conference Call and Webcast Information:
The conference call will take place on April 13,
2020, at 4:30 p.m. ET. The call can be heard live on the investor
relations section of the company's website at www.amarincorp.com,
or via telephone by dialing 877-869-3847 within the United States,
201-689-8261 from outside the United States. A replay of the call
will be made available for a period of two weeks following the
conference call. To hear a replay of the call, dial 877-481-4010,
PIN: 34132. A replay of the call will also be available through the
company's website shortly after the call.
About Amarin
Amarin Corporation plc is a rapidly growing,
innovative pharmaceutical company focused on developing and
commercializing therapeutics to cost-effectively improve
cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent
ethyl), is available by prescription in the United States, Canada,
Lebanon and the United Arab Emirates. Amarin, together with its
commercial partners in select geographies, is pursuing additional
regulatory approvals for VASCEPA in China, the European Union and
the Middle East. For more information about Amarin, visit
www.amarincorp.com.
Availability of Other Information About
Amarin
Investors and others should note that Amarin
communicates with its investors and the public using the company
website (www.amarincorp.com), the investor relations website
(investor.amarincorp.com), including but not limited to investor
presentations and investor FAQs, Securities and Exchange Commission
filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could
be deemed to be material information. As a result, Amarin
encourages investors, the media, and others interested in Amarin to
review the information that is posted on these channels, including
the investor relations website, on a regular basis. This list of
channels may be updated from time to time on Amarin’s investor
relations website and may include social media channels. The
contents of Amarin’s website or these channels, or any other
website that may be accessed from its website or these channels,
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933.
Amarin Contact Information
Investor and Media Inquiries:Elisabeth
SchwartzInvestor RelationsAmarin Corporation plcIn U.S.: +1 (908)
719-1315investor.relations@amarincorp.com (investor
inquiries)PR@amarincorp.com (media inquiries)
Lee M. SternSolebury TroutIn U.S.: +1 (646)
378-2992lstern@soleburytrout.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024